We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

118 hedge funds and large institutions have $561M invested in Nurix Therapeutics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

173,900% more call options, than puts

Call options by funds: $1.74M | Put options by funds: $1K

150% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 8

122% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 23

11% more funds holding

Funds holding: 106 → 118 (+12)

1% less capital invested

Capital invested by funds: $568M → $561M (-$7.2M)

8.58% less ownership

Funds ownership: 100.1% → 91.52% (-8.6%)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
118
Holders Change
+12
Holders Change %
+11.32%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
20
Increased
51
Reduced
23
Closed
8
Calls
$1.74M
Puts
$1K
Net Calls
+$1.74M
Net Calls Change
-$400K

Top Buyers

1
AIM
ARK Investment Management
Florida
+$8.04M
2
Goldman Sachs
Goldman Sachs
New York
+$7.81M
3
WA
Wasatch Advisors
Utah
+$6.24M
4
BlackRock
BlackRock
New York
+$5.82M
5
N
Nuveen
North Carolina
+$3.61M

Top Sellers

1
TGI
TRV GP III
Massachusetts
-$24.4M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$16.1M
3
EAM
Eventide Asset Management
Massachusetts
-$14.6M
4
FCMI
Foresite Capital Management IV
California
-$8.58M
5
SCM
Soleus Capital Management
Connecticut
-$7.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$4.36M +$2.06M +130,423 +64%
PIM
27
Ponoi II Management
California
$4.26M – – –
PM
28
Ponoi Management
California
$4.26M – – –
HMC
29
Harvard Management Company
Massachusetts
$4.1M – – –
WFA
30
WestHill Financial Advisors
California
$3.69M – – –
Nomura Holdings
31
Nomura Holdings
Japan
$3.1M -$1.07M -67,797 -22%
UBS AM
32
UBS AM
Illinois
$3M -$217K -13,713 -6%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$2.07M +$365K +23,057 +17%
Citadel Advisors
34
Citadel Advisors
Florida
$1.81M +$2.19M +138,679 New
CSS
35
Cubist Systematic Strategies
Connecticut
$1.72M +$1M +63,235 +92%
Rafferty Asset Management
36
Rafferty Asset Management
New York
$1.71M +$947K +59,860 +84%
Bank of America
37
Bank of America
North Carolina
$1.7M +$673K +42,527 +48%
Citigroup
38
Citigroup
New York
$1.57M +$716K +45,253 +60%
JRP
39
Jasper Ridge Partners
California
$1.25M -$47.1K -2,976 -3%
Ensign Peak Advisors
40
Ensign Peak Advisors
Utah
$1.13M +$34.3K +2,170 +3%
Barclays
41
Barclays
United Kingdom
$1.1M +$1.29M +81,760 +2,994%
AllianceBernstein
42
AllianceBernstein
Tennessee
$1.08M +$153K +9,639 +13%
Swiss National Bank
43
Swiss National Bank
Switzerland
$1.03M – – –
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$996K +$1.21M +76,415 New
Voloridge Investment Management
45
Voloridge Investment Management
Florida
$989K +$1.2M +75,876 New
Ohio Public Employees Retirement System (OPERS)
46
Ohio Public Employees Retirement System (OPERS)
Ohio
$974K +$255K +16,087 +27%
Wellington Management Group
47
Wellington Management Group
Massachusetts
$971K +$339K +21,425 +40%
Renaissance Technologies
48
Renaissance Technologies
New York
$955K -$714K -45,100 -38%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$913K +$112K +7,051 +11%
Los Angeles Capital Management
50
Los Angeles Capital Management
California
$882K +$861K +54,390 +410%
1
2
3 4 5

NRIX Hedge Fund Activity: Q3 2022 in Review

118 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2022, worth a combined $561M — down 1.3% from $568M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new NRIX positions and 8 closed out — a net gain of 12 holders — while 51 added to existing stakes and 23 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $8.04M. The largest seller was TRV GP III, exiting entirely with an estimated $24.4M sold.

  • 118 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2022, up from 106 in Q2 2022.
  • Funds reported $561M of Nurix Therapeutics stock for Q3 2022, down 1.3% quarter-over-quarter.
  • 20 funds opened new Nurix Therapeutics positions in Q3 2022 and 8 closed out, a net change of +12 holders.
  • The largest Nurix Therapeutics buyer in Q3 2022 was ARK Investment Management, an estimated $8.04M added.
  • The largest Nurix Therapeutics seller in Q3 2022 was TRV GP III, an estimated $24.4M sold.

Based on aggregated 13F filings for Q3 2022.